NCT06715579|RecruitingDMC
Cardiac Angiosarcoma International Registry
CAIR
Loading search results
CAIR
Sponsor study identifier
observational
500
1 country
1
Study Start
May 1, 2025
Actual (reported)Primary Completion
May 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 28, 2024
Actual (reported)December 4, 2024
Actual (reported)May 1, 2025
Actual (reported)May 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
May 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
6-month overall survival
6 months
1-year overall survival
1 year
6-month progression free survival
6 months
1-year progression free survival
1 year
3-year progression free survival
3 years
6-month event-free survival
6 months
All patients diagnosed with Cardiac Angiosarcoma
Yeolyan Hematology and Oncology Center
Yerevan, 0014, Armenia
Shushan Hovsepyan, MD
Immune Oncology Research Institute, Yerevan, Armenia
Amalya Sargsyan, MD
Immune Oncology Research Institute, Yerevan, Armenia
Ruzanna Papyan, MD
Immune Oncology Research Institute, Yerevan, Armenia
First Submitted
November 28, 2024
First Posted
December 4, 2024
Study Start
May 1, 2025
Actual (reported)Primary Completion
May 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Contact the study team to confirm eligibility.
Study Completion
May 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
February 18, 2026
Record last verified: 2026-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: